Company Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
73.26 USD -0.58% Intraday chart for Gilead Sciences, Inc. -2.73% -9.57%

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees: 18,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
27,281 100.0 % 27,116 100.0 % -0.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
71.7 %
18,884 69.2 % 19,438 71.7 % +2.93%
Europe
15.9 %
4,469 16.4 % 4,310 15.9 % -3.56%
Other International
12.4 %
3,928 14.4 % 3,368 12.4 % -14.26%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 19-02-28
Director of Finance/CFO 54 15-12-31
Chief Tech/Sci/R&D Officer - 21-04-11
Chief Tech/Sci/R&D Officer 61 19-10-31
Investor Relations Contact - 20-12-31
Corporate Officer/Principal - -
Corporate Officer/Principal 54 22-07-17
Corporate Officer/Principal - -
Human Resources Officer 48 17-10-31
Corporate Officer/Principal - 18-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 69 20-10-16
Director/Board Member 71 17-12-31
Director/Board Member 65 Jan. 31
Director/Board Member 69 09-07-28
Director/Board Member 70 18-05-08
Director/Board Member 53 20-06-14
Chief Executive Officer 58 19-02-28
Director/Board Member 75 20-01-27
Director/Board Member 56 16-08-18
Director/Board Member 70 20-12-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,245,774,616 1,244,607,278 ( 99.91 %) 0 99.91 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
8.976 %
111,822,428 8.976 % 8 062 M $
BlackRock Advisors LLC
7.472 %
93,089,266 7.472 % 6 712 M $
Capital Research & Management Co. (World Investors)
6.692 %
83,364,123 6.692 % 6 011 M $
Capital Research & Management Co. (Global Investors)
4.789 %
59,657,126 4.789 % 4 301 M $
59,536,425 4.779 % 4 293 M $
Dodge & Cox
2.673 %
33,295,023 2.673 % 2 401 M $
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.205 %
27,471,926 2.205 % 1 981 M $
Geode Capital Management LLC
2.029 %
25,274,185 2.029 % 1 822 M $
Wellington Management Co. LLP
1.495 %
18,630,134 1.495 % 1 343 M $
Eaton Vance Management
1.429 %
17,801,718 1.429 % 1 284 M $
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000361 %
8,986 0.000361 % 324 759 $
Bram Bradesco Asset Management S/A DTVM
0.000240 %
5,980 0.000240 % 216 121 $
Western Asset Management Company DTVM Ltda.
0.000030 %
738 0.000030 % 26 672 $

Holdings

NameEquities%Valuation
31,532,781 34.70% 603,222,101 $
16,707,477 25.35% 594,651,018 $
6,720,803 13.80% 442,363,253 $
4,126,119 9.57% 112,106,653 $
4,854,443 4.76% 54,029,951 $
18,759,465 23.00% 14,407,269 $
1,089,468 19.87% 13,934,296 $
16,635,286 14.58% 12,260,206 $
2,931,467 6.07% 4,191,998 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
Pharmaceuticals: Major

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
73.26 USD
Average target price
86.45 USD
Spread / Average Target
+18.00%
Consensus